• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

糖尿病合并慢性肾脏病患者的心血管疾病事件再发风险。

Risk for recurrent cardiovascular disease events among patients with diabetes and chronic kidney disease.

机构信息

Department of Epidemiology, University of Alabama At Birmingham, 1665 University Blvd, RPHB 140J, Birmingham, AL, 35233-0013, USA.

Mount Sinai Heart, Icahn School of Medicine At Mount Sinai, New York, NY, USA.

出版信息

Cardiovasc Diabetol. 2021 Mar 1;20(1):58. doi: 10.1186/s12933-021-01247-0.

DOI:10.1186/s12933-021-01247-0
PMID:33648518
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7923492/
Abstract

BACKGROUND

Adults who have experienced multiple cardiovascular disease (CVD) events have a very high risk for additional events. Diabetes and chronic kidney disease (CKD) are each associated with an increased risk for recurrent CVD events following a myocardial infarction (MI).

METHODS

We compared the risk for recurrent CVD events among US adults with health insurance who were hospitalized for an MI between 2014 and 2017 and had (1) CVD prior to their MI but were free from diabetes or CKD (prior CVD), and those without CVD prior to their MI who had (2) diabetes only, (3) CKD only and (4) both diabetes and CKD. We followed patients from hospital discharge through December 31, 2018 for recurrent CVD events including coronary, stroke, and peripheral artery events.

RESULTS

Among 162,730 patients, 55.2% had prior CVD, and 28.3%, 8.3%, and 8.2% had diabetes only, CKD only, and both diabetes and CKD, respectively. The rate for recurrent CVD events per 1000 person-years was 135 among patients with prior CVD and 110, 124 and 171 among those with diabetes only, CKD only and both diabetes and CKD, respectively. Compared to patients with prior CVD, the multivariable-adjusted hazard ratio for recurrent CVD events was 0.92 (95%CI 0.90-0.95), 0.89 (95%CI: 0.85-0.93), and 1.18 (95%CI: 1.14-1.22) among those with diabetes only, CKD only, and both diabetes and CKD, respectively.

CONCLUSION

Following MI, adults with both diabetes and CKD had a higher risk for recurrent CVD events compared to those with prior CVD without diabetes or CKD.

摘要

背景

经历过多次心血管疾病(CVD)事件的成年人再次发生心血管事件的风险非常高。糖尿病和慢性肾脏病(CKD)均与心肌梗死(MI)后再次发生 CVD 事件的风险增加有关。

方法

我们比较了 2014 年至 2017 年期间因 MI 住院的美国有医疗保险的成年人中,(1)在 MI 前患有 CVD 但无糖尿病或 CKD(既往 CVD),以及(2)在 MI 前无 CVD 但患有(2)糖尿病,(3)CKD 仅患有,和(4)患有糖尿病和 CKD 的患者再次发生 CVD 事件的风险。我们从患者出院开始随访至 2018 年 12 月 31 日,以监测再次发生的 CVD 事件,包括冠状动脉、中风和外周动脉事件。

结果

在 162730 名患者中,55.2%的患者有既往 CVD,28.3%、8.3%和 8.2%的患者分别仅患有糖尿病、CKD 和糖尿病合并 CKD。每 1000 人年发生 CVD 事件的发生率在既往 CVD 患者中为 135,在仅患有糖尿病、CKD 仅患有和糖尿病合并 CKD 的患者中分别为 110、124 和 171。与既往 CVD 患者相比,多变量调整后的 CVD 事件再发风险比为 0.92(95%CI 0.90-0.95)、0.89(95%CI:0.85-0.93)和 1.18(95%CI:1.14-1.22),分别为仅患有糖尿病、CKD 仅患有和糖尿病合并 CKD 的患者。

结论

在 MI 后,患有糖尿病合并 CKD 的成年人再次发生 CVD 事件的风险高于无糖尿病或 CKD 的既往 CVD 患者。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5fc6/7923492/81e41144979b/12933_2021_1247_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5fc6/7923492/81e41144979b/12933_2021_1247_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5fc6/7923492/81e41144979b/12933_2021_1247_Fig1_HTML.jpg

相似文献

1
Risk for recurrent cardiovascular disease events among patients with diabetes and chronic kidney disease.糖尿病合并慢性肾脏病患者的心血管疾病事件再发风险。
Cardiovasc Diabetol. 2021 Mar 1;20(1):58. doi: 10.1186/s12933-021-01247-0.
2
The risk trajectory of different cardiovascular morbidities associated with chronic kidney disease among patients with newly diagnosed diabetes mellitus: a propensity score-matched cohort analysis.新诊断糖尿病患者中与慢性肾脏病相关的不同心血管疾病发病率的风险轨迹:倾向评分匹配队列分析。
Cardiovasc Diabetol. 2021 Apr 24;20(1):86. doi: 10.1186/s12933-021-01279-6.
3
Serum Fractalkine (CX3CL1) and Cardiovascular Outcomes and Diabetes: Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study.血清 fractalkine(CX3CL1)与心血管结局及糖尿病:慢性肾功能不全队列(CRIC)研究的结果
Am J Kidney Dis. 2015 Aug;66(2):266-73. doi: 10.1053/j.ajkd.2015.01.021. Epub 2015 Mar 17.
4
Impacts of chronic kidney disease and diabetes on cardiovascular mortality in a general Japanese population: A 20-year follow-up of the NIPPON DATA90 study.慢性肾脏病和糖尿病对日本普通人群心血管死亡率的影响:日本国家数据库90研究的20年随访
Eur J Prev Cardiol. 2017 Mar;24(5):505-513. doi: 10.1177/2047487316679904. Epub 2016 Nov 19.
5
Prognostic Relation Between Severity of Diabetes Mellitus (On or Off Insulin) ± Chronic Kidney Disease with Cardiovascular Risk After Percutaneous Coronary Intervention.糖尿病严重程度(使用或不使用胰岛素) ± 经皮冠状动脉介入治疗后心血管风险与慢性肾脏病的预后关系。
Am J Cardiol. 2018 Jan 15;121(2):168-176. doi: 10.1016/j.amjcard.2017.10.004. Epub 2017 Oct 19.
6
Kidney disease as a risk factor for recurrent cardiovascular disease and mortality.肾脏疾病作为心血管疾病复发和死亡的一个风险因素。
Am J Kidney Dis. 2004 Aug;44(2):198-206. doi: 10.1053/j.ajkd.2004.04.024.
7
International Validation of the Thrombolysis in Myocardial Infarction (TIMI) Risk Score for Secondary Prevention in Post-MI Patients: A Collaborative Analysis of the Chronic Kidney Disease Prognosis Consortium and the Risk Validation Scientific Committee.国际验证心肌梗死后血栓溶解治疗(TIMI)风险评分在 MI 后患者二级预防中的应用:慢性肾脏病预后联盟和风险验证科学委员会的协作分析。
J Am Heart Assoc. 2018 Jul 7;7(14):e008426. doi: 10.1161/JAHA.117.008426.
8
Cardiovascular events and death after myocardial infarction or ischemic stroke in an older Medicare population.老年医疗保险参保人群中心肌梗死或缺血性中风后的心血管事件及死亡情况。
Clin Cardiol. 2019 Mar;42(3):391-399. doi: 10.1002/clc.23160. Epub 2019 Feb 25.
9
Chronic kidney disease and diabetes associated with long-term outcomes in patients receiving percutaneous coronary intervention.慢性肾脏病和糖尿病与接受经皮冠状动脉介入治疗患者的长期预后相关。
BMC Cardiovasc Disord. 2017 Sep 11;17(1):242. doi: 10.1186/s12872-017-0673-4.
10
Prognostic Effect of Isolated Nocturnal Hypertension in Chinese Patients With Nondialysis Chronic Kidney Disease.单纯夜间高血压对中国非透析慢性肾脏病患者的预后影响
J Am Heart Assoc. 2016 Oct 10;5(10):e004198. doi: 10.1161/JAHA.116.004198.

引用本文的文献

1
Cardiovascular Risks With SGLT2 Inhibitors in Clinical Practice Among Patients With Type 2 Diabetes.在患有 2 型糖尿病的患者中,临床实践中 SGLT2 抑制剂的心血管风险。
JAMA Netw Open. 2024 Oct 1;7(10):e2441765. doi: 10.1001/jamanetworkopen.2024.41765.
2
Prognostic significance of plasma SDF-1 in acute ischemic stroke patients with diabetes mellitus: the CATIS trial.糖尿病合并急性缺血性脑卒中患者血浆 SDF-1 的预后意义:CATIS 试验。
Cardiovasc Diabetol. 2023 Oct 10;22(1):274. doi: 10.1186/s12933-023-01996-0.
3
Association between estimated glomerular filtration rate slope and cardiovascular disease among individuals with and without diabetes: a prospective cohort study.

本文引用的文献

1
Effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomes-Systematic review and meta-analysis of randomized placebo-controlled trials.钠-葡萄糖共转运蛋白 2 抑制剂对心血管和肾脏结局的影响——随机安慰剂对照试验的系统评价和荟萃分析。
Am Heart J. 2021 Feb;232:10-22. doi: 10.1016/j.ahj.2020.10.064. Epub 2020 Oct 24.
2
Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular Disease.达格列净对伴有或不伴有心血管疾病的慢性肾脏病患者临床结局的影响。
Circulation. 2021 Feb 2;143(5):438-448. doi: 10.1161/CIRCULATIONAHA.120.051675. Epub 2020 Nov 13.
3
估算肾小球滤过率斜率与糖尿病患者和非糖尿病患者心血管疾病的关系:一项前瞻性队列研究。
Cardiovasc Diabetol. 2023 Oct 4;22(1):270. doi: 10.1186/s12933-023-02008-x.
4
Ambulatory Blood Pressure Monitoring as a Useful Tool in the Cardiological Assessment of Pancreas Transplant Recipients with Type 1 Diabetes.动态血压监测作为1型糖尿病胰腺移植受者心脏评估的有用工具
Diagnostics (Basel). 2023 Aug 22;13(17):2724. doi: 10.3390/diagnostics13172724.
5
Health-related patterns and chronic kidney disease in the Brazilian population: National Health Survey, 2019.巴西人口的健康相关模式与慢性肾脏病:2019 年全国健康调查。
Front Public Health. 2023 Apr 6;11:1090196. doi: 10.3389/fpubh.2023.1090196. eCollection 2023.
6
Real-World Prescription Patterns and Barriers Related to the Use of Sodium-Glucose Cotransporter 2 Inhibitors among Korean Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease.韩国 2 型糖尿病合并心血管疾病患者中钠-葡萄糖共转运蛋白 2 抑制剂的实际处方模式及使用障碍。
Diabetes Metab J. 2022 Sep;46(5):701-712. doi: 10.4093/dmj.2022.0002. Epub 2022 Jun 3.
SGLT2 inhibitors for non-diabetic kidney disease: drugs to treat CKD that also improve glycaemia.
用于非糖尿病肾病的钠-葡萄糖协同转运蛋白2抑制剂:治疗慢性肾脏病且能改善血糖水平的药物。
Clin Kidney J. 2020 Oct 9;13(5):728-733. doi: 10.1093/ckj/sfaa198. eCollection 2020 Oct.
4
Heterogeneity of antidiabetic treatment effect on the risk of major adverse cardiovascular events in type 2 diabetes: a systematic review and meta-analysis.2 型糖尿病患者主要不良心血管事件风险的降糖治疗效果的异质性:系统评价和荟萃分析。
Cardiovasc Diabetol. 2020 Sep 29;19(1):154. doi: 10.1186/s12933-020-01133-1.
5
Preventing major adverse cardiovascular events by SGLT-2 inhibition in patients with type 2 diabetes: the role of kidney.通过 SGLT-2 抑制预防 2 型糖尿病患者的主要不良心血管事件:肾脏的作用。
Cardiovasc Diabetol. 2020 Mar 19;19(1):35. doi: 10.1186/s12933-020-01010-x.
6
Two-year outcomes among stable high-risk patients following acute MI. Insights from a global registry in 25 countries.急性心肌梗死后稳定高危患者的两年预后。来自25个国家全球注册研究的见解。
Int J Cardiol. 2020 Jul 15;311:7-14. doi: 10.1016/j.ijcard.2020.01.070. Epub 2020 Jan 28.
7
Major adverse cardiovascular events in people with chronic kidney disease in relation to disease severity and diabetes status.慢性肾脏病患者的主要不良心血管事件与疾病严重程度和糖尿病状态有关。
PLoS One. 2019 Aug 28;14(8):e0221044. doi: 10.1371/journal.pone.0221044. eCollection 2019.
8
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.GLP-1 受体激动剂在 2 型糖尿病患者中的心血管、死亡率和肾脏结局:心血管结局试验的系统评价和荟萃分析。
Lancet Diabetes Endocrinol. 2019 Oct;7(10):776-785. doi: 10.1016/S2213-8587(19)30249-9. Epub 2019 Aug 14.
9
Rationale and tutorial for analysing and reporting sex differences in cardiovascular associations.分析和报告心血管关联中性别差异的原理及教程。
Heart. 2019 Nov;105(22):1701-1708. doi: 10.1136/heartjnl-2019-315299. Epub 2019 Aug 1.
10
Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial.依洛尤单抗在 FOURIER 试验中慢性肾脏病的疗效和安全性。
J Am Coll Cardiol. 2019 Jun 18;73(23):2961-2970. doi: 10.1016/j.jacc.2019.03.513.